Combining Enzalutamide With PARP Inhibitors: Pharmaceutically Induced BRCAness

Oncotarget - United States
doi 10.18632/oncotarget.22074
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Androgen Receptor Inhibitor–induced “BRCAness” and PARP Inhibition Are Synthetically Lethal for Castration-Resistant Prostate Cancer

Science Signaling
BiochemistryCell BiologyMolecular Biology
2017English

PARP Inhibitors in Ovarian Cancer

2013English

BRCA2 Abrogation Triggers Innate Immune Responses Potentiated by Treatment With PARP Inhibitors

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2019English

PARP Inhibitors: Extending Benefit Beyond BRCA Mutant Cancers

Clinical Cancer Research
Cancer ResearchOncology
2019English

PARP Inhibitors and Stratified Treatment of Prostate Cancer

Expert Review of Anticancer Therapy
OncologyPharmacology
2016English

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Cancer Cell
Cancer ResearchOncologyCell Biology
2011English

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy

Frontiers in Pharmacology
Pharmacology
2020English

Combining Angiotensin-Receptor Blockers With Angiotensin-Converting-Enzyme Inhibitors

CMAJ
Medicine
2011English

Extending the Scope of PARP Inhibitors in Ovarian Cancer

The Lancet Oncology
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy